Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States

doi:10.19803/j.1672-8629.2021.03.08

Abstract

Abstract: Objective To provide references for the management of safety information in prescription drug labeling in China. Methods By consulting regulations and literatures, format requirements and revision procedures of safety information in prescription drug labeling were compared among China, the United States and Japan. Results Compared with the United States and Japan, content and format requirements in Chinese regulations and guidelines for the safety-concerning sections of prescription drug labeling were relatively brief,and the implementation was too flexible. The revision process and notification after revision lack detailed basis for implementation. Conclusion It is suggested that both foreign and domestic experts should be widely consulted in combination with the experience of other countries. The safety information management system of the labeling could be further improved based on a comprehensive revision of the“Provisions on the Administration of Pharmaceutical Directions and Labels”and its detailed rules.

Key words: prescription drugs, labeling, safety information, revision

CLC Number:

R951

CONG Duanduan, XUE Wei, LIU Yue, QI Wenyuan, LIU Xiaohui, WANG Juan, LI Kexin, HU Xin. Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 245-249.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2021.03.08

https://zgywjj.magtechjournal.com/EN/Y2021/V18/I3/245

References

[1] Fu SY,Yang Y,Yu JR.Game and regulatory suggestions in the revision process of drug instructions for domestic pharmaceutical companies[J]. Chinese Pharmaceutical Journal(中国药学杂志), 2018, 53(15): 1318-1322.
[2] Hu XY, Liang YQ, Zeng YL, et al.A comparative analysis of the pharmacovigilance system in China and the United States[J].Chinese Journal of Rational Drug Use(中国合理用药探索), 2020, 17(2): 21-25.
[3] Zhao TT, Zhao JZ, Wang HX.Considerations of standardize domestic approved drug package inserts[J]. The Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2020, 36(14): 2153-2155.
[4] Standing Committee of the National People's Congress of the People's Republic of China. The Drug Administration Law of the People's Republic of China (Order of the President of the People's Republic of China, No.31, 2019) [EB/OL]. (2019-08-26)[2020-08-12]. http://www.npc.gov.cn/npc/c30834/201908/26a6b28dd83546d79d17f90c62e59461. shtml
[5] State Administration for Market Regulation. Provisions for drug registration(SAMR Order No. 27,2020)[EB/OL].(2020-01-22)[2020-08-12]. http://www.gov.cn/zhengce/zhengceku/2020-04/01/content_5498012. htm.
[6] State Food and Drug Administration. Notice on the issuance of the detailed requirements of labelling for chemical drugs and biological products(SFDA[2006],No.202) [EB/OL].(2006-05-10)[2020-08-12]. https://www.nmpa.gov.cn/xxgk/fgwj/gzwj/gzwjyp/20060510010101566. html
[7] State Food and Drug Administration. Provisions for drug insert sheets and labels (SFDA Decree No.24,2006) [EB/OL]. (2006-03-15)[2020-08-14]. http://www.gov.cn/flfg/2006-03/16/content_228465. htm.
[8] The Federal Government. Specific requirements on content and format of labeling for human prescription drug and biological products; older drugs not described in 201.56(b)(1) (Code of Federal Regulations Title 21 Part 201 Sec. 201.80, 21CFR §201.80)[EB/OL].(2017-01-03)[2020-08-11]. https://ecfr.federalregister.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-C/section-201. 80.
[9] The Federal Government. Requirements on content and format of labeling for human prescription drug and biological products. (Code of Federal Regulations Title 21 Part 201 Sec. 201.56, 21CFR §201.56)[EB/OL].(2017-01-03)[2020-08-11]. https://ecfr.federalregister.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201. 56.
[10] The Federal Government. Specific requirements on content and format of labeling for human prescription drug and biological products described in § 201.56(b)(1). (Code of Federal Regulations Title 21 Part 201 Sec. 201.57, 21CFR § 201.57)[EB/OL].(2017-01-03)[2020-08-11]. https://ecfr.federalregister.gov/current/title-21/chapter-I/subchapter-C/part-201/subpart-B/section-201. 57.
[11] U.S. Food and Drug Administration. Warnings and precautions, contraindications,boxed warning sections of labeling for human prescription drug and biological products- content and format[EB/OL].(2011-10) [2020-08-11]. https://www.fda.gov/media/71866/download.
[12] U.S. Food and Drug Administration. Adverse reactions section of labeling for human prescription drug and biological products-content and format [EB/OL].(2006-01) [2020-08-11]. https://www.fda. gov/media/72139/download
[13] U.S. Food and Drug Administration. Pregnancy, iactation,reproductive potential: labeling for human prescription drug and biological products-content and format(Draft guidance) [EB/OL]. (2020-07) [2020-08-11]. https://www.fda.gov/media/90160/download.
[14] Pharmaceutical Safety and Environmental Health Bureau. Instructions for package inserts of prescription drugs (PSEHB Notification No.0608-1) [EB/OL].(2017-06-08) [2020-08-14]. http://efpia.jp/link/PSEHB-Notification-No.0608-1_Eng. pdf
[15] Pharmaceutical Safety and Environmental Health Bureau. Points to consider for the instructions for package inserts of prescription drugs (PSEHB/SD notification No.0608-1). [EB/OL]. (2017-06-08) [2020-08-14]. http://www.phrma-jp.org/wordpress/wp-content/uploads/2019/05/PSEHBSD-Notification-No.0608-1_E_1.1. pdf
[16] Chang YC, Ye H.Analysis of the laws and rules of drug package inserts in China[J]. Chinese Pharmaceutical Affairs(中国药事), 2010, 24(3): 225-229.
[17] U.S. Food and Drug Administration. Safety labeling changes-implementation of section 505(o)(4) of the FD&C act [EB/OL]. (2013-07) [2020-08-11]. https://www.fda.gov/media/116594/download
[18] The Federal Government. Supplements and other changes to an approved NDA (Code of Federal Regulations Title 21 Part 314 Sec. 314.70, 21CFR §314.70)[EB/OL]. (2017-01-03)[2020-08-11]. https://ecfr.federalregister.gov/current/title-21/chapter-I/subchapter-D/part-314/subpart-B/section-314. 70.
[19] The Federal Government. Changes to an approved application (Code of federal regulations title 21 Part 601 Sec. 601.12, 21CFR §601.12)[EB/OL].(2017-01-03)[2020-08-11]. https://ecfr.federalregister.gov/current/title-21/chapter-I/subchapter-F/part-601/subpart-C/section-601. 12.
[20] Japan Pharmaceutical Manufacturers Association. Pharmaceutical administration and regulations in Japan 2020[EB/OL]. (2020)[2020-08-15] http://www.jpma.or.jp/english/parj/pdf/2020. pdf.
[21] Pharmaceutical and Food Safety Bureau. Guideline on revision of precautions and other information(PFSB/SD notification No.0929-2) [EB/OL]. (2014-09-29)[2020-08-15]. https://www.pmda.go.jp/files/000153160. pdf.
[22] Safety Division, Pharmaceutical and Food Safety Bureau. Notice concerning revisions to the“standard workflow for the revision of drug product package inserts”[EB/OL]. ( 2014-11-25)[2020-08-15]. https://www.pmda.go.jp/files/000213324. pdf.